Article
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Blood - 10 Dec 2020
Sallman David A, McLemore Amy F, Aldrich Amy L, Komrokji Rami S, McGraw Kathy L, Dhawan Abhishek, Geyer Susan, Hou Hsin-An, Eksioglu Erika A, Sullivan Amy, Warren Sarah, MacBeth Kyle J, Meggendorfer Manja, Haferlach Torsten, Boettcher Steffen, Ebert Benjamin L, Al Ali Najla H, Lancet Jeffrey E, Cleveland John L, Padron Eric, List Alan F
Abstract excerpt
Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise pathogenetic mechanisms underlying these inferior outcomes have not been delineated. In this study, we characterized the immunological features of the malignant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.